The history of MF59® adjuvant: A phoenix that arose from the ashes

Expert Review of Vaccines

Volumn 12, Issue 1, 2013, Pages 13-30

  O'Hagan, Derek T ^a   Ott, Gary S ^b   Van Nest, Gary ^c   Rappuoli, Rino ^d   Del Giudice, Giuseppe ^d  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^b Dynavax Technologies Corporation   (United States)

^c MEDIMMUNE   (United States)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

emulsion; influenza vaccine; MF59 ; pandemic influenza vaccine; vaccine adjuvant

Indexed keywords

ADJUVANT; AF03; DIETHYLSTILBESTROL; FREUND ADJUVANT; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPOSOME; MALARIA VACCINE; MIFAMURTIDE; POLYSORBATE; POLYSORBATE 80; SORBITAN TRIOLEATE; SQUALENE; TEMURTIDE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

2009 H1N1 INFLUENZA; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EMULSION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; MEMORY; MICROPARTICLE ENZYME IMMUNOASSAY; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANIMALS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; EMULSIONS; FEMALE; HISTORY, 20TH CENTURY; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MICE; POLYSORBATES; PREGNANCY; SQUALENE;

EID: 84871578453     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.140     Document Type: Review

References (136)

1. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and sassembly of hepatitis B virus surface antigen particles in yeast. Nature 298(5872), 347-350 (1982).
2. Freund J, Casals J, Hosmer E. Sensitization and antibody formation after injection of Tubercle Bacilli and paraffin oil. Proc. Soc. Exp. Biol. Med. 37, 509-513 (1937).
3. Hilleman MR. Critical appraisal of emulsified oil adjuvants applied to viral vaccines. Prog. Med. Virol. 8, 131-182 (1966).
4. Salk JE, Laurent AM, Bailey ML. Direction of research on vaccination against influenza; new studies with immunologic adjuvants. Am. J. Public Health Nations. Health 41(6), 669-677 (1951).
5. Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 2(3), 370-383 (1980).
6. Page WF, Chubb M, Feng X et al. National estimates of seroincidence and seroprevalence for herpes simplex virus type 1 and type 2 among US military adults aged 18 to 29 years. Sex. Transm. Dis. 39(4), 241-250 (2012).
7. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1(1), 111-118 (2002).
8. Audran R, Cachat M, Lurati F et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun. 73(12), 8017-8026 (2005).
9. Masihi KN, Lange W, Brehmer W, Ribi E. Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects. Int. J. Immunopharmacol. 8(3), 339-345 (1986).
10. Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Methods 95(2), 157-168 (1986).
11. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6, 277-296 (1995).
12. Brito LA, Chan M, Baudner B et al. An alternative renewable source of squalene for use in emulsion adjuvants. Vaccine 29(37), 6262-6268 (2011).
13. Ott G. The adjuvant MF59: a ten year perspective. In: Vaccine Adjuvants: Preparation Methods and Research Protocols. O'Hagan D (Ed.). Humana Press, NY, USA, 211-228 (2000).
14. Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis. 174(6), 1168-1175 (1996).
15. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180(8), 5402-5412 (2008).
16. Calabro S, Tortoli M, Baudner BC et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29(9), 1812-1823 (2011).
17. Mosca F, Tritto E, Muzzi A et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl Acad. Sci. USA 105(30), 10501-10506 (2008).
18. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59-an innately attractive adjuvant formulation. Vaccine 30(29), 4341-4348 (2012).
19. Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharm. Biotechnol. 6, 141-228 (1995).
20. Ellouz F, Adam A, Ciorbaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59(4), 1317-1325 (1974).
21. Waters RV, Terrell TG, Jones GH. Uveitis induction in the rabbit by muramyl dipeptides. Infect. Immun. 51(3), 816-825 (1986).
22. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat. Immunol. 7(12), 1250-1257 (2006).
23. Kenney R, Edelman R. New Generation Vaccines. Marcel Dekker, Inc., NY, USA (2004).
24. Wintsch J, Chaignat CL, Braun DG et al. Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J. Infect. Dis. 163(2), 219-225 (1991).
25. Keitel W, Couch R, Bond N, Adair S, Van Nest G, Dekker C. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 11(9), 909-913 (1993).
26. Keefer MC, Graham BS, McElrath MJ et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 12(8), 683-693 (1996).
27. Kahn JO, Sinangil F, Baenziger J et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIVinfected human volunteers. J. Infect. Dis. 170(5), 1288-1291 (1994).
28. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19(17-19), 2673-2680 (2001).
29. Baldo V, Baldovin T, Floreani A, Minuzzo M, Trivello R. Response to influenza vaccine in people with non-protective HI antibody titers. Eur. J. Epidemiol. 21(11), 843-845 (2006).
30. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49(3), 177-184 (2003).
31. Baldo V, Baldovin T, Angiolelli A et al. Immunogenicity and safety of an MF59®-adjuvanted and a non-adjuvanted inactivated subunit influenza vaccine in adults affected by chronic diseases. J. Clin. Trials 2(2) (2012).
32. Vesikari T, Pellegrini M, Karvonen A et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr. Infect. Dis. J. 28(7), 563-571 (2009).
33. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 26(26), 3209-3222 (2008).
34. Puig-Barberà J, Diez-Domingo J, Pérez Hoyos S, Belenguer Varea A, González Vidal D. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 23(3), 283-289 (2004).
35. Puig-Barberà J, Díez-Domingo J, Varea AB et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 25(42), 7313-7321 (2007).
36. Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol. Infect. 133(4), 687-693 (2005).
37. Mannino S, Villa M, Apolone G et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am. J. Epidemiol. 176(6), 527-533 (2012).
38. Asa PB, Cao Y, Garry RF. Antibodies to squalene in Gulf War syndrome. Exp. Mol. Pathol. 68(1), 55-64 (2000).
39. Fulco CE, Liverman CT, Sox HC. Gulf War and Health: Depleted Uranium, Pyridostigmine Bromide, Sarin, Vaccines. National Academy Press, Washington, DC, USA, 267-324 (2000).
40. Del Giudice G, Fragapane E, Bugarini R et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin. Vaccine Immunol. 13(9), 1010-1013 (2006).
41. Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357(9272), 1937-1943 (2001).
42. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006).
43. Atmar RL, Keitel WA, Patel SM et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis. 43(9), 1135-1142 (2006).
44. Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191(8), 1210-1215 (2005).
45. Stöhr K. Vaccinate before the next pandemic? Nature 465(7295), 161 (2010).
46. Galli G, Hancock K, Hoschler K et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA 106(19), 7962-7967 (2009).
47. Galli G, Medini D, Borgogni E et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877-3882 (2009).
48. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 25(39-40), 6852-6862 (2007).
49. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol. 61(1), 94-99 (2000).
50. Kojimahara N, Maeda A, Kase T, Yamaguchi N. Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine. Vaccine 24(33-34), 5966-5969 (2006).
51. Ansaldi F, Bacilieri S, Durando P et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 26(12), 1525-1529 (2008).
52. Del Giudice G, Hilbert AK, Bugarini R et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24(16), 3063-3065 (2006).
53. Legrand J, Vergu E, Flahault A. Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 24(44-46), 6605-6611 (2006).
54. Ansaldi F, Zancolli M, Durando P et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59-and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 28(25), 4123-4129 (2010).
55. Camilloni B, Neri M, Lepri E, Iorio AM. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. Vaccine 27(31), 4099-4103 (2009).
56. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 27(45), 6291-6295 (2009).
57. O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev. Vaccines 10(4), 447-462 (2011).
58. Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 292(11), 1333-1340 (2004).
59. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2), 179-186 (2003).
60. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst. Rev. 2, CD004879 (2008).
61. Vesikari T, Becker T, Gajdos V et al. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (Pro-Quad(®)) in infants from 9 months of age. Vaccine 30(20), 3082-3089 (2012).
62. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.). 70(4), 767-777 (1972).
63. Black S, Nicolay U, Vesikari T et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr. Infect. Dis. J. 30(12), 1081-1085 (2011).
64. Tsai T, Brestrich G, Beygo J et al. Neutralization antibody titre correlate of influenza vaccine efficacy in 6 month to
65. Wilkinson TM, Li CK, Chui CS et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18(2), 274-280 (2012).
66. Sasaki S, He XS, Holmes TH et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS ONE 3(8), e2975 (2008).
67. Greenberg ME, Lai MH, Hartel GF et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N. Engl. J. Med. 361(25), 2405-2413 (2009).
68. Clark TW, Pareek M, Hoschler K et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361(25), 2424-2435 (2009).
69. Yasuda Y, Komatsu R, Matsushita K et al. Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children. Adv. Ther. 27(7), 444-457 (2010).
70. Hatz C, Cramer JP, Vertruyen A et al. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. Vaccine 30(32), 4820-4827 (2012).
71. Song JY, Cheong HJ, Seo YB et al. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults. Clin. Vaccine Immunol. 19(5), 638-641 (2012).
72. Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G. A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Vaccine 30(23), 3470-3477 (2012).
73. Arguedas A, Soley C, Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N. Engl. J. Med. 362(4), 370-372 (2010).
74. Block SL, Ruiz-Palacios GM, Guerrero ML, Beygo J, Sales V, Holmes SJ. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six-to less than thirty-six-month-old children. Pediatr. Infect. Dis. J. 31(7), e92-e98 (2012).
75. Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to 9 years of age. Pediatr. Infect. Dis. J., 31, 4, e59-e65.2012.
76. Wrammert J, Koutsonanos D, Li GM et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208(1), 181-193 (2011).
77. Faenzi E, Zedda L, Bardelli M et al. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. Vaccine 30(27), 4086-4094 (2012).
78. Cheong HJ, Song JY, Heo JY et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clin. Vaccine Immunol. 18(8), 1358-1364 (2011).
79. Khurana S, Chearwae W, Castellino F et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2(15), 15ra5 (2010).
80. Khurana S, Verma N, Yewdell JW et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3(85), 85ra48 (2011).
81. Durando P, Fenoglio D, Boschini A et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and-seronegative adults. Clin. Vaccine Immunol. 15(2), 253-259 (2008).
82. Viganò A, Giacomet V, Pariani E et al. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. Clin. Vaccine Immunol. 18(9), 1503-1509 (2011).
83. Fabbiani M, Di Giambenedetto S, Sali M et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine 29(16), 2836-2839 (2011).
84. Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS ONE 6(1), e16496 (2011).
85. Kajaste-Rudnitski A, Galli L, Nozza S et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 25(2), 177-183 (2011).
86. Pariani E, Boschini A, Amendola A et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Vaccine 29(49), 9209-9213 (2011).
87. Palma R. Safety and immunogenicity of a monovalent MF50®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. Biologicals 40, 134-139 (2012).
88. Esposito S, Tagliaferri L, Daleno C et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine 29(8), 1677-1682 (2011).
89. Mosby LG, Rasmussen SA, Jamieson DJ. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am. J. Obstet. Gynecol. 205(1), 10-18 (2011).
90. Tsai T, Kyaw MH, Novicki D, Nacci P, Rai S, Clemens R. Exposure to MF59-adjuvanted influenza vaccines during pregnancy-a retrospective analysis. Vaccine 28(7), 1877-1880 (2010).
91. Heikkinen T, Young J, van Beek E et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am. J. Obstet. Gynecol. 207(3), 177.e1-177.e8 (2012).
92. Huang WT, Chen WC, Teng HJ et al. Adverse events following pandemic A (H1N1) 2009 monovalent vaccines in pregnant women-Taiwan, November 2009-August 2010. PLoS ONE 6(8), e23049 (2011).
93. Zaman K, Roy E, Arifeen SE et al. Effectiveness of maternal influenza immunization in mothers and infants. N. Engl. J. Med. 359(15), 1555-1564 (2008).
94. Pasternak B, Svanström H, Mølgaard-Nielsen D et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. JAMA 308(2), 165-174 (2012).
95. Luecke RW, Meeting DT. The FASB explores accounting for future cash flows. Healthc. Financ. Manage. 55(3), 56-61 (2001).
96. van Puijenbroek EP, Broos N, van Grootheest K. Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in The Netherlands. Drug Saf. 33(12), 1097-1108 (2010).
97. Meier S, Bel M, L'huillier A et al.; H1N1 Epidemiology Study Group of Geneva. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 29(19), 3548-3557 (2011).
98. Rahier JF, Papay P, Salleron J et al.; European Crohn's and Colitis Organisation (ECCO). H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 60(4), 456-462 (2011).
99. Morel S, Didierlaurent A, Bourguignon P et al. Adjuvant System AS03 containing a-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29(13), 2461-2473 (2011).
100. Banzhoff A, Haertel S, Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum. Vaccin. 7(5), 539-548 (2011).
101. Tsai TF, Crucitti A, Nacci P et al. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand. J. Infect. Dis. 43(9), 702-706 (2011).
102. Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7(3), e33536 (2012).
103. Partinen M, Saarenpää-Heikkilä O, Ilveskoski I et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 7(3), e33723 (2012).
104. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines 6(5), 699-710 (2007).
105. Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines 2(2), 197-203 (2003).
106. Podda A. A safe and potent adjuvant for human use. In: Immunopotentiators in Modern Vaccines. Schijns V, O'Hagan DT (Eds). Elsevier Press, Amsterdam, The Netherlands, 149 (2005).
107. Corey L, Langenberg AG, Ashley R et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282(4), 331-340 (1999).
108. Straus SE, Wald A, Kost RG et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J. Infect. Dis. 176(5), 1129-1134 (1997).
109. Mascola JR. Herpes simplex virus vaccines-why don't antibodies protect? JAMA 282(4), 379-380 (1999).
110. Nitayaphan S, Khamboonruang C, Sirisophana N et al. A Phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais. AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. Vaccine 18(15), 1448-1455 (2000).
111. Heineman TC, Clements-Mann ML, Poland GA et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17(22), 2769-2778 (1999).
112. Pass RF, Zhang C, Evans A et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360(12), 1191-1199 (2009).
113. Ott G, Barchfeld GL, Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 13(16), 1557-1562 (1995).
114. Baudner BC, Ronconi V, Casini D et al. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm. Res. 26(6), 1477-1485 (2009).
115. Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 14(6), 478-484 (1996).
116. Cataldo DM, Van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 15(16), 1710-1715 (1997).
117. Della Cioppa G, Nicolay U, Lindert K et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59® adjuvant: results from a dosefinding clinical trial in older adults. Hum. Vaccin. Immunother. 8(2), 216-227 (2012).
118. Keitel W, Groth N, Lattanzi M et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a Phase 1/2 clinical trial. Vaccine 28(3), 840-848 (2010).
119. Vecchi S, Bufali S, Skibinski DA, O'Hagan DT, Singh M. Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations. J. Pharm. Sci. 101(1), 17-20 (2012).
120. Seubert A, Calabro S, Santini L et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc. Natl Acad. Sci. USA 108(27), 11169-11174 (2011).
121. Whitley RJ, Roizman B. Herpes simplex viruses: is a vaccine tenable? J. Clin. Invest. 110(2), 145-151 (2002).
122. Tong NK, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 68(5), 2298-2303 (2005).
123. Cherpelis S, Jin X, Gettie A et al. DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques. Immunol. Lett. 79(1-2), 47-55 (2001).
124. AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J. Infect. Dis. 183(4), 563-570 (2001).
125. Otten GR, Chen M, Doe B, zur Megede J, Barnett S, Ulmer J. Quantitative assessment of antigen-specific CD8+ T cells in the mouse: application to vaccine research. Immunol. Lett. 85(2), 215-222 (2003).
126. Otten G, Schaefer M, Doe B et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22(19), 2489-2493 (2004).
127. Otten GR, Schaefer M, Doe B et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J. Virol. 79(13), 8189-8200 (2005).
128. O'Hagan DT, Singh M, Dong C et al. Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 23(5), 672-680 (2004).
129. Bernstein DI, Schleiss MR, Berencsi K et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J. Infect. Dis. 185(5), 686-690 (2002).
130. Gómez-Román VR, Florese RH, Peng B et al. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J. Acquir. Immune Defic. Syndr. 43(3), 270-277 (2006).
131. O'Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant-'the long and winding road'. Drug Discov. Today 14(11-12), 541-551 (2009).
132. De Donato S, Granoff D, Minutello M et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17(23-24), 3094-3101 (1999).
133. Zuccotti GV, Pariani E, Scaramuzza A et al. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A (H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with Type 1 diabetes mellitus. Diabet. Med. 28(12), 1530-1536 (2011).
134. Elkayam O, Amir S, Mendelson E et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res. (Hoboken) 63(7), 1062-1067 (2011).
135. Alghisi F, Palma P, Montemitro E et al. Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. Thorax 66(3), 259-260 (2011).
136. Zuccotti G, Pogliani L, Pariani E, Amendola A, Zanetti A. Transplacental antibody transfer following maternal immunization with a pandemic 2009 influenza A(H1N1) MF59-adjuvanted vaccine. JAMA 304(21), 2360-2361 (2010).